Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
6.44 ^USD	+1.74%		-1.38%	+41.54%

Mar. 19	North American Morning Briefing : Stock Futures -2-	DJ
Mar. 14	Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 14, 2024 at 04:26 pm EDT

Larimar Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 36.95 million compared to USD 35.36 million a year ago. Basic loss per share from continuing operations was USD 0.84 compared to USD 1.37 a year ago.

Latest news about Larimar Therapeutics, Inc.

North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Larimar Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Sector Update: Health Care Stocks Gain Premarket Tuesday	Mar. 12	MT
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
Larimar Therapeutics Doses 1st Patient in Study of Movement Disorder Treatment	Mar. 11	MT
Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich?S Ataxia	Mar. 11	CI
Top Midday Gainers	Feb. 14	MT
Larimar Therapeutics Starts Public Offering of Common Shares, Pre-Funded Warrants	Feb. 14	MT
Top Midday Gainers	Feb. 13	MT
Guggenheim Adjusts Price Target on Larimar Therapeutics to $25 From $14, Maintains Buy Rating	Feb. 13	MT
Citigroup Adjusts Price Target on Larimar Therapeutics to $10 From $4.50, Maintains Buy Rating	Feb. 13	MT
JMP Securities Adjusts Price Target on Larimar Therapeutics to $25 From $17, Maintains Market Outperform Rating	Feb. 13	MT
Larimar Therapeutics Says Potential Friedreich's Ataxia Drug Well-Tolerated in Phase 2 Study	Feb. 12	MT
Transcript : Larimar Therapeutics, Inc. - Special Call	Feb. 12
Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia	Feb. 12	CI
North American Morning Briefing : Stocks Futures -2-	Nov. 20	DJ
Citigroup Upgrades Larimar Therapeutics to Buy From Neutral, Price Target is $4.50	Nov. 17	MT
Larimar Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors	23-10-03	CI
Larimar Therapeutics, Inc.(NasdaqGM:LRMR) added to S&P Global BMI Index	23-09-18	CI
Larimar Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Larimar Therapeutics Shares Rise 10% After FDA Clears CTI-1601 Trial	23-07-25	DJ
Larimar Therapeutics Gets FDA Clearance to Proceed With Trials; Shares Rise	23-07-25	MT
Transcript : Larimar Therapeutics, Inc. - Special Call	23-07-25

Chart Larimar Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Companyâs lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.44 USD

Average target price

19.86 USD

Spread / Average Target

+208.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LARIMAR THERAPEUTICS, INC.	+41.54%	411M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs